Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas (2009)
Fujita, K.,
Ichikawa, W.,
Yamamoto, W.,
Endo, H.,
Nagashima, F.,
Tanaka, R.,
...
Background: S-1 is an oral anticancer agent that combines tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate. The recommended initial dose of S-1 is 120 mg/day for patients...
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy (2008)
Akiyama, Y.,
Fujita, K.,
Nagashima, F.,
Yamamoto, W.,
Endo, H.,
Sunakawa, Y.,
...
A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group (1999)
Narabayashi, M,
Takeyama, K,
Fukutomi, T,
Tokuda, Y,
Tajima, T,
Okumura, A,
...
Primary low-grade lymphoma of mucosa-associated lymphoid tissue of the urinary bladder: a case report with special reference to the use of ancillary diagnostic studies (1999)
Ando, K,
Matsuno, Y,
Kanai, Y,
Sakamoto, M,
Fujimoto, H,
Narabayashi, M,
...
Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines (1999)
Ando, M,
Narabayashi, M,
Watanabe, T,
Kamiya, Y,
Togitani, K,
Tanosaki, R,
...
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma (1998)
Tobinai, K.,
Kobayashi, Y.,
Narabayashi, M.,
Ogura, M.,
Kagami, Y.,
Morishima, Y.,
...
Background In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high response rates with only mild toxic effects in relapsed B-cell...
Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment (1998)
Yamamoto, N,
Katsumata, N,
Watanabe, T,
Omuro, Y,
Ando, M,
Narabayashi, M,
...
Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group (1997)
Tobinai, K,
Ogura, M,
Hotta, T,
Kobayashi, Y,
Narabayashi, M,
Suzuki, R,
...
Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan (1996)
Katsumata, N,
Matsuno, Y,
Nakayama, H,
Takenaka, T,
Kobayashi, Y,
Takeyama, K,
...
Eyelid metastasis from breast cancer showing marked response to chemotherapy (1995)
Zhang, GJ,
Adachi, I,
Yin, DF,
Narabayashi, M,
Tokue, Y,
Watanabe, T,
...
MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial (1993)
Watanabe, T,
Narabayashi, M,
Haga, S,
Yamada, Y,
Kawamura, E,
Enomoto, K,
...
Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group (1993)
Tobinai, K,
Kohno, A,
Shimada, Y,
Watanabe, T,
Tamura, T,
Takeyama, K,
...
Hemorrhagic cystitis associated with allogeneic and autologous bone marrow transplantation for malignant neoplasms in adults (1993)
Kohno, A,
Takeyama, K,
Narabayashi, M,
Tamayose, K,
Watanabe, T,
Adachi, I,
...
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Adachi, I.,
Watanabe, T.,
Takashima, S.,
Narabayashi, M.,
Horikoshi, N.,
Aoyama, H.,
...
A late phase II clinical trial of RP56976 (docetaxel), derived from Taxus baccata was performed to evaluate anti-tumour activity, time to progression and clinical toxicity in patients with advanced...
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Ando, M.,
Watanabe, T.,
Sasaki, Y.,
Ying, D. F.,
Omuro, Y.,
Katsumata, N.,
...
To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of...